Ravulizumab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.
A complement-blocking infusion reduced kidney protein loss by 43% more than placebo in IgA nephropathy patients, with fewer serious side effects, offering a new treatment avenue.
Ravulizumab (C5 complement inhibitor, IV every 8 weeks) produced a 43.4% greater reduction in 24-hour urinary protein-to-creatinine ratio vs placebo at Week 34 in adults with IgA nephropathy (P<0.001), with fewer serious adverse events (4.6% vs 9.0%) and no meningococcal infections. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- Phase 3 RCT (interim analysis)
- Category
- rare_diseases_high_unmet_need
- Maturity
- Potentially Practice-Changing
- Journal
- N Engl J Med
Why it surfaced
High-impact NEJM Phase 3 interim analysis demonstrating significant complement C5 inhibition efficacy in IgA nephropathy—a rare progressive kidney disease with high unmet need—representing a potentially practice-changing mechanism-based treatment supported by robust RCT data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.